Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1ZG5E
|
|||
| Drug Name |
OTSA-101-DTPA-90Y
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Synovial sarcoma [ICD-11: 2B5A; ICD-9: 171] | Phase 1 | [1] | |
| Company |
University of Tokyo/Centre Leon-Berard
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Frizzled-10 (FZD10) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01469975) First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (SYNFRIZZ). U.S. National Institutes of Health. | |||
| REF 2 | A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 8;18(1):646. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.